Austin Health Research Online

David K Lau

View Statistics Email Alert RSS Feed

Claim profile

Loading... 2 0 20 0 false

Credit Name

David K Lau

Full Name

Lau, David K

Department

Olivia Newton-John Cancer Research Institute

Loading... 3 0 20 0 false

Refined By:

Author: Jenkins, Laura J

Results 1-3 of 3 (Search time: 0.007 seconds).

Refman/EndNote EndNote Bibtex RefWorks Excel CSV Send via email

	Publication Year	Title	Author(s)
1	2-May-2022	Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.	Weickhardt, Andrew J ; Lau, David K ; Hodgson-Garms, Margeaux; Lavis, Austen; Jenkins, Laura J; Vukelic, Natalia; Ioannidis, Paul; Luk, Ian Y; Mariadason, John M
2	22-Feb-2021	Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK.	Lau, David K ; Luk, Ian Y; Jenkins, Laura J; Martin, Andrew; Williams, David S ; Schoffer, Kael L; Chionh, Fiona; Buchert, Michael; Sjoquist, Katrin; Boussioutas, Alex; Hayes, Sarah A; Ernst, Matthias ; Weickhardt, Andrew J ; Pavlakis, Nick; Tebbutt, Niall C ; Mariadason, John M
3	22-Nov-2019	Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets.	Lau, David K ; Mouradov, Dmitri; Wasenang, Wiphawan; Luk, Ian Y; Scott, Cameron M; Williams, David S ; Yeung, Yvonne H ; Limpaiboon, Temduang; Iatropoulos, George F ; Jenkins, Laura J; Reehorst, Camilla M; Chionh, Fiona; Nikfarjam, Mehrdad ; Croagh, Daniel; Dhillon, Amardeep S; Weickhardt, Andrew J ; Muramatsu, Toshihide; Saito, Yoshimasa; Tebbutt, Niall C ; Sieber, Oliver M; Mariadason, John M